Based on ratings from 2 stock analysts, the Amphastar Pharmaceuticals Inc stock price is expected to increase by 21.36% in 12 months. This is calculated by using the average 12-month stock price forecast for Amphastar Pharmaceuticals Inc. The lowest target is $55.00 and the highest is $71.00. Please note analyst price targets are not guaranteed and could be missed completely.
Amphastar Pharmaceuticals Inc has a total of 2 Wall St Analyst ratings. There are 2 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that Amphastar Pharmaceuticals Inc will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
---|---|---|---|---|
david amsellem Piper Sandler | Buy | $71.0 | reiterated | Nov 30, 2023 |
nico chen DBS | Buy | $55.0 | maintained | Nov 24, 2023 |
jason gerberry Bank of America Securities | Hold | $63.0 | initiatedcoverage | Nov 17, 2023 |
serge belanger Needham | Hold | None | maintained | Nov 9, 2023 |
glen santangelo Jefferies | Buy | $70.0 | initiatedcoverage | Jul 25, 2023 |
jacob hughes Wells Fargo | Hold | None | rated | Jun 13, 2023 |
tim chiang Capital One Financial | Buy | $44.0 | initiatedcoverage | Jul 29, 2022 |
david steinberg Jefferies | Buy | $33.0 | maintained | Mar 10, 2022 |
elliot wilbur Raymond James | Hold | None | maintained | Jul 1, 2021 |
gary nachman BMO Capital | Hold | $21.0 | maintained | May 11, 2020 |
alan carr Needham | Buy | $24.0 | reiterated | Mar 13, 2018 |
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredient (API). It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation; and Vasopressin to increase blood pressure in adults with vasodilatory shock. Further, the company distributes recombinant human insulin APIs and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
When did it IPO
2014
Staff Count
1,615
Country
United States
Sector/Industry
Healthcare/Drug Manufacturers—Specialty & Generic
CEO
Dr. Yongfeng Zhang Ph.D.
Market Cap
$2.46B
In 2023, AMPH generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that AMPH's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2019
Revenue From 2020
Revenue From 2021
Revenue From 2022
PSMT-USD
$80.24
PRFT-USD
$70.33
PRVA-USD
$20.93
NTLA-USD
$27.74
PSEC-USD
$5.83
BMBL-USD
$13.1